Patterns and trends of idarucizumab use in an Italian region: a probabilistic record-linkage approach in a real-life setting (original) (raw)

Idarucizumab is a specific reversal agent for dabigatran, approved in Europe in 2015, but its use in real-world settings is not well documented. This study aimed to analyze the usage patterns of idarucizumab in Tuscany, Italy, utilizing a probabilistic record-linkage claims database. Over the study period from 2015 to 2018, data showed 26,821 person-years (PYs) of dabigatran usage with 112 administrations of idarucizumab identified. A significant portion of the administrations was linked to male patients over 80 years old, primarily for emergency surgeries or life-threatening bleeding. The findings emphasize the utility of the Tuscany database for monitoring idarucizumab's safety and effectiveness in post-marketing surveillance.